Skip to main content

Johnson David Michael's Form 4 filing

Aura Biosciences, Inc.AURA · filed Oct 5, 2023

Accession no.
0000950170-23-052244
Filed
Oct 5, 2023
Trade date
Oct 3-4, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $168.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Johnson David MichaelCIK 0001808098Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 3, 2023Common StockPPurchaseAcquired+13,500$8.27F1+$111,64543,500Direct
Oct 4, 2023Common StockPPurchaseAcquired+6,566$8.61F2+$56,533.2650,066Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.00 to $8.51, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.52 to $8.66, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)